News & Publications
Immodulon presents at International Society for Advancement of Cytometry CYTO Virtual 2020 conference on biomarker considerations in immunomodulator clinical trials
Presentation on different technologies to assess the impact of IMM-101 on the immune system in the approved phase 3 clinical trial for COVID-19 in cancer patients Uxbridge, UK – 4th August 2020 – Immodulon, the Immuno-oncology company, today announces that a...
Immodulon and Champalimaud Foundation announce collaboration to investigate IMM-101 in difficult to treat cancers
Poster presentation at CICON and oral and poster presentation at BSI demonstrated the immunomodulatory effects of IMM-101 in pre-clinical models Oral and poster presentation at Pancreatic Cancer Symposium reported results from the IMAGE 1 open label Phase II study in...
Expansion of collaboration with Erasmus Medical Centre in metastatic pancreatic cancer
Additional investigator-initiated phase I/II study planned to investigate the safety and efficacy of IMM101 in limited metastatic pancreatic cancer; study could start by the end of 2020 Uxbridge, UK – 27 July 2020 – Immodulon, the immuno-oncology company, is pleased...
Immodulon announces that IMM-101 will be evaluated in world-first, prophylactic immuneboosting strategy for COVID-19 in cancer patients
Poster presentation at CICON and oral and poster presentation at BSI demonstrated the immunomodulatory effects of IMM-101 in pre-clinical models Oral and poster presentation at Pancreatic Cancer Symposium reported results from the IMAGE 1 open label Phase II study in...
Immodulon announce FDA approval of an IND for a phase I/II study of IMM-101 in advanced sarcoma
The phase I/II trial will recruit up to 42 participants with inoperable leiomyosarcoma or dedifferentiated liposarcoma Uxbridge, UK – 28 May 2020 – Immodulon, the immuno-oncology company, today announces that the Company has received confirmation from the US Food and...
Immodulon announces appointment of Dr. Cellia Habita as Chief Medical Officer
Dr. Habita brings deep expertise in clinical drug development, as the Company continues to seek to progress its uniquely differentiated clinical programmes in immuno-oncology Uxbridge, UK – 14 April 2020 – Immodulon, the immuno-oncology company, announces the...
Immodulon announces Notice of Allowance for two U.S. Patent Applications related to IMM-101…
Immodulon announces Notice of Allowance for two U.S. Patent Applications related to IMM-101 in combination with Immune Checkpoint Inhibitors Claims cover methods of treating pancreatic cancer or melanoma with IMM-101 in combination with anti-PD-L1, anti-PD1 or...
Immodulon announces presentations at CICON, BSI and Pancreatic Cancer Symposium
Poster presentation at CICON and oral and poster presentation at BSI demonstrated the immunomodulatory effects of IMM-101 in pre-clinical models Oral and poster presentation at Pancreatic Cancer Symposium reported results from the IMAGE 1 open label Phase II study in...
Immodulon presents long-term survival data of IMM-101 in patients with advanced melanoma at The Society for Melanoma Research 2019 Congress
Positive results from phase 1 follow up study supports current phase 2 clinical trial of IMM-101 in combination with checkpoint inhibitor therapy Immodulon, the immuno-oncology company, today announces that long-term survival data from its phase 1 study in 18 patients...
Investigator-initiated phase I/II LAPC-2 study of IMM-101 in locally advanced pancreatic cancer
Phase 1/2 study to investigate safety and efficacy of IMM-101 in locally advanced pancreatic cancer Uxbridge, UK, 13 September 2019 – Immodulon, the immuno-oncology company, today announces that the Department of Surgery at the Erasmus Medical Center in Rotterdam is...